ArticleBreast cancer research : BCR2026

Development and cross-validation of a novel multi-omic assay to assess locoregional recurrence risk and adjuvant therapy benefit in early-stage hormone receptor positive invasive breast cancer patients.

Troy Bremer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.